Mustang Bio (MBIO) Stock Price, News & Analysis

Company Overview

Mustang Bio, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas. On the rare disease front, Mustang Bio is developing gene therapy candidates aimed at lysosomal storage disorders and other inherited metabolic conditions, utilizing proprietary vector designs and manufacturing processes to deliver functional copies of deficient genes. Mustang Bio’s research collaborations and licensing agreements with leading academic institutions underpin its approach to translational science and clinical development.

Founded in 2015 and headquartered in Worcester, Massachusetts, Mustang Bio operates in North America and Europe, conducting multi‐center clinical studies to evaluate safety and efficacy of its product candidates. The company’s management team comprises industry veterans with expertise in cell therapy development, regulatory affairs and biomanufacturing. Through strategic partnerships and its own manufacturing capabilities, Mustang Bio seeks to advance first-in-class therapies from the laboratory to patients in need.

Key Stats

• Today's Range: $1.61 to $1.65
• 50-Day Range: $1.36 to $2.65
• 52-Week Range: $0.89 to $21.95
• Volume: 22,012 shs
• Average Volume: 2.28 million shs
• Market Capitalization: $11.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mustang Bio Stock Analysis - MarketRank™

Mustang Bio scored higher than 9% of companies evaluated by MarketBeat, and ranked 920th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mustang Bio.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mustang Bio are expected to grow in the coming year, from ($35.00) to ($19.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mustang Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mustang Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.36% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 17.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mustang Bio does not currently pay a dividend.

Dividend Growth

Mustang Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.36% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 17.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mustang Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.21% of the stock of Mustang Bio is held by insiders.

Percentage Held by Institutions

Only 9.95% of the stock of Mustang Bio is held by institutions.

MBIO Stock Analysis - Frequently Asked Questions

How have MBIO shares performed this year?

Mustang Bio's stock was trading at $8.85 at the beginning of the year. Since then, MBIO stock has decreased by 81.7% and is now trading at $1.62.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) released its quarterly earnings results on Friday, August, 8th. The company reported ($0.19) earnings per share (EPS) for the quarter.

When did Mustang Bio's stock split?

Shares of Mustang Bio reverse split before market open on Thursday, January 16th 2025.The 1-50 reverse split was announced on Tuesday, January 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBIO
• CIK: 1680048
• Web: www.mustangbio.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($78.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -29.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.11) per share
• Price / Book: -0.77

Miscellaneous

• Outstanding Shares: 7,240,000
• Free Float: 7,225,000
• Market Cap: $11.73 million
• Optionable: Not Optionable
• Beta: 2.23